MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

TransMedics Group Inc

Abrir

SetorSaúde

91.01 -3.32

Visão Geral

Variação de preço das ações

24h

Atual

Mín

90.97

Máximo

95.02

Indicadores-chave

By Trading Economics

Rendimento

2.6M

6.9M

Vendas

13M

122M

P/E

Médio do Setor

81.981

57.333

EPS

0.19

Margem de lucro

5.638

Funcionários

728

EBITDA

3.2M

16M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+8.4% upside

Dividendos

By Dow Jones

Próximos Ganhos

8 de mai. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

397M

3B

Abertura anterior

94.33

Fecho anterior

91.01

Pontuação Técnica

By Trading Central

Confiança

Weak Bullish Evidence

TransMedics Group Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

20 de set. de 2024, 03:29 UTC

Principais Notícias

Dow Jones Futures: Meta, Apple, Tesla Lead New Buys In Big Rally. Pay Attention To This Key Shift. -- IBD

Comparação entre Pares

Variação de preço

TransMedics Group Inc Previsão

Preço-alvo

By TipRanks

8.4% parte superior

Previsão para 12 meses

Média 100 USD  8.4%

Máximo 125 USD

Mínimo 80 USD

Com base em 8 analistas de Wall Street que oferecem metas de preço de 12 meses para TransMedics Group Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

8 ratings

5

Comprar

3

Manter

0

Vender

Pontuação Técnica

By Trading Central

88.48 / N/ASuporte e Resistência

Curto Prazo

Weak Bullish Evidence

Médio Prazo

Very Strong Bullish Evidence

Longo Prazo

Weak Bullish Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre TransMedics Group Inc

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.